| Year |
Citation |
Score |
| 2023 |
Kuser-Abali G, Zhang Y, Szeto P, Zhao P, Masoumi-Moghaddam S, Fedele CG, Leece I, Huang C, Cheung JG, Ameratunga M, Noguchi F, Andrews MC, Wong NC, Schittenhelm RB, Shackleton M. UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. Oncogene. PMID 36906655 DOI: 10.1038/s41388-023-02631-8 |
0.735 |
|
| 2022 |
Gangoda L, Schenk RL, Tai L, Szeto P, Cheung JG, Strasser A, Lessene G, Shackleton M, Herold MJ. Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs. Cell Death & Disease. 13: 301. PMID 35379799 DOI: 10.1038/s41419-022-04776-y |
0.752 |
|
| 2021 |
Vergara IA, Mintoff CP, Sandhu S, McIntosh L, Young RJ, Wong SQ, Colebatch A, Cameron DL, Kwon JL, Wolfe R, Peng A, Ellul J, Dou X, Fedele C, Boyle S, ... ... Shackleton M, et al. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications. 12: 1434. PMID 33664264 DOI: 10.1038/s41467-021-21576-8 |
0.741 |
|
| 2020 |
Lynch FA, Katona L, Jefford M, Smith AB, Shaw J, Dhillon HM, Ellen S, Phipps-Nelson J, Lai-Kwon J, Milne D, Russell L, Dax V, Diggens J, Kent H, Button-Sloan A, ... ... Shackleton M, et al. Feasibility and Acceptability of : A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma. Journal of Clinical Medicine. 9. PMID 32937942 DOI: 10.3390/Jcm9092969 |
0.328 |
|
| 2020 |
Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, Moore M, Shackleton M, Haydon A, John T, Mitchell PLR, Markman B, Briggs P, Parakh S. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clinical Lung Cancer. PMID 32778511 DOI: 10.1016/J.Cllc.2020.06.001 |
0.33 |
|
| 2020 |
Dall GV, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell SM, Ashworth A, Anderson RL, Risbridger GP, Shackleton M, Britt KL. Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice. Breast Cancer Research and Treatment. PMID 32696317 DOI: 10.1007/S10549-020-05804-1 |
0.35 |
|
| 2020 |
Zhang X, Yang L, Szeto P, Abali GK, Zhang Y, Kulkarni A, Amarasinghe K, Li J, Vergara IA, Molania R, Papenfuss AT, McLean C, Shackleton M, Harvey KF. The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. Oncogene. PMID 32561850 DOI: 10.1038/S41388-020-1362-9 |
0.786 |
|
| 2020 |
Zhang X, Yang L, Vergara I, Szeto P, Zhang Y, Papenfuss A, Shackleton M, Harvey K. Abstract IA03: The Hippo pathway in melanoma Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-Ia03 |
0.487 |
|
| 2019 |
Samuel E, Moore M, Voskoboynik M, Shackleton M, Haydon A. An update on adjuvant systemic therapies in melanoma. Melanoma Management. 6: MMT28. PMID 31807279 DOI: 10.2217/Mmt-2019-0009 |
0.326 |
|
| 2019 |
Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30838379 DOI: 10.1093/Annonc/Mdz048 |
0.321 |
|
| 2019 |
Zhang X, Tang JZ, Vergara IA, Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, Mcintosh L, Mitchell KA, Shaw E, Rizos H, Long GV, Hayward N, McArthur GA, ... ... Shackleton M, et al. Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. Molecular Cancer Research : McR. PMID 30833299 DOI: 10.1158/1541-7786.Mcr-18-0407 |
0.772 |
|
| 2017 |
Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, ... ... Shackleton M, et al. Whole-genome landscapes of major melanoma subtypes. Nature. PMID 28467829 DOI: 10.1038/Nature22071 |
0.358 |
|
| 2017 |
Noguchi F, Inui S, Fedele C, Shackleton M, Itami S. Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma. Molecular Cancer Therapeutics. 16: 936-947. PMID 28223427 DOI: 10.1158/1535-7163.Mct-15-0235 |
0.777 |
|
| 2016 |
Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Frankel AE, Johnson TM, DeBerardinis RJ, Morrison SJ. Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7: 13080. PMID 27681157 DOI: 10.1038/ncomms13080 |
0.759 |
|
| 2016 |
Paul PJ, Raghu D, Chan AL, Gulati T, Lambeth L, Takano E, Herold MJ, Hagekyriakou J, Vessella RL, Fedele C, Shackleton M, Williams ED, Fox S, Williams S, Haupt S, et al. Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. Oncogene. PMID 27641331 DOI: 10.1038/Onc.2016.159 |
0.78 |
|
| 2016 |
Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, ... ... Shackleton M, et al. A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology. PMID 27617737 DOI: 10.1038/Nbt.3674 |
0.755 |
|
| 2016 |
Eskiocak U, Ramesh V, Gill JG, Zhao Z, Yuan SW, Wang M, Vandergriff T, Shackleton M, Quintana E, Johnson TM, DeBerardinis RJ, Morrison SJ. Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7: 12336. PMID 27545456 DOI: 10.1038/Ncomms12336 |
0.81 |
|
| 2016 |
Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget. PMID 27340778 DOI: 10.18632/Oncotarget.10216 |
0.809 |
|
| 2016 |
Ebert LM, Tan LY, Johan MZ, Min KK, Cockshell MP, Parham KA, Betterman KL, Szeto P, Boyle S, Silva L, Peng A, Zhang Y, Ruszkiewicz A, Zannettino AC, Gronthos S, ... ... Shackleton M, et al. A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis. PMID 27338829 DOI: 10.1007/S10456-016-9520-Y |
0.771 |
|
| 2016 |
Boyle SE, Fedele CG, Corbin V, Wybacz E, Szeto P, Lewin J, Young RJ, Wong A, Fuller R, Spillane J, Speakman D, Donahoe S, Pohl M, Gyorki D, Henderson MA, ... ... Shackleton M, et al. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research. PMID 27325642 DOI: 10.1158/0008-5472.Can-15-2377 |
0.723 |
|
| 2015 |
Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, ... ... Shackleton M, et al. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research. PMID 26627015 DOI: 10.1158/0008-5472.Can-15-1877 |
0.38 |
|
| 2015 |
Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, Radaelli E, Al-Haddawi M, Tan SY, Hermans E, Amant F, ... ... Shackleton M, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. The Journal of Clinical Investigation. PMID 26595814 DOI: 10.1172/Jci82534 |
0.453 |
|
| 2015 |
Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, et al. Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology. PMID 26517638 DOI: 10.1097/Pat.0000000000000324 |
0.36 |
|
| 2015 |
Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling. 8: ra82. PMID 26286024 DOI: 10.1126/Scisignal.Aab1111 |
0.778 |
|
| 2015 |
He M, Lovell J, Ng BL, Spillane J, Speakman D, Henderson MA, Shackleton M, Gyorki DE. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. Journal of Surgical Oncology. 111: 980-4. PMID 26080731 DOI: 10.1002/Jso.23938 |
0.356 |
|
| 2015 |
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Shackleton M, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521: 489-94. PMID 26017449 DOI: 10.1038/Nature14410 |
0.356 |
|
| 2015 |
Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer (Oxford, England : 1990). 51: 1435-43. PMID 25980594 DOI: 10.1016/J.Ejca.2015.04.010 |
0.334 |
|
| 2015 |
Tang Jz, Zhang X, Vergara I, Papenfuss A, Harvey K, Shackleton M. Abstract B157: YAP is a promising target in cutaneous melanoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B157 |
0.395 |
|
| 2014 |
Gyorki DE, Spillane J, Speakman D, Shackleton M, Henderson MA. Current management of advanced melanoma: a transformed landscape. Anz Journal of Surgery. 84: 612-7. PMID 24842394 DOI: 10.1111/Ans.12673 |
0.338 |
|
| 2014 |
Schröder J, Hsu A, Boyle SE, Macintyre G, Cmero M, Tothill RW, Johnstone RW, Shackleton M, Papenfuss AT. Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads. Bioinformatics (Oxford, England). PMID 24389656 DOI: 10.1093/Bioinformatics/Btt767 |
0.723 |
|
| 2013 |
Piskounova E, Quintana E, Shackleton M, Johnson TM, Morrison SJ. Abstract C9: Human melanoma metastasis in NSG mice correlates with clinical outcome in patients Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-C9 |
0.807 |
|
| 2012 |
Quintana E, Piskounova E, Shackleton M, Weinberg D, Eskiocak U, Fullen DR, Johnson TM, Morrison SJ. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Science Translational Medicine. 4: 159ra149. PMID 23136044 DOI: 10.1126/Scitranslmed.3004599 |
0.784 |
|
| 2012 |
Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, ... ... Shackleton M, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine. 18: 1239-47. PMID 22820643 DOI: 10.1038/Nm.2863 |
0.782 |
|
| 2012 |
Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. Plos One. 7: e36924. PMID 22666336 DOI: 10.1371/Journal.Pone.0036924 |
0.409 |
|
| 2011 |
Shackleton M. Pulling RANK: are some melanoma cells more malignant than others? The Journal of Investigative Dermatology. 131: 814-6. PMID 21407234 DOI: 10.1038/Jid.2011.18 |
0.449 |
|
| 2011 |
Carter CC, McNamara LA, Onafuwa-Nuga A, Shackleton M, Riddell J, Bixby D, Savona MR, Morrison SJ, Collins KL. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host & Microbe. 9: 223-34. PMID 21402361 DOI: 10.1016/J.Chom.2011.02.005 |
0.607 |
|
| 2010 |
Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 18: 510-23. PMID 21075313 DOI: 10.1016/J.Ccr.2010.10.012 |
0.804 |
|
| 2010 |
Shackleton M. Moving targets that drive cancer progression. The New England Journal of Medicine. 363: 885-6. PMID 20818851 DOI: 10.1056/Nejmcibr1006328 |
0.411 |
|
| 2010 |
Shackleton M. Melanoma stem cells--are there devils in the detail? Pigment Cell & Melanoma Research. 23: 693-4. PMID 20704685 DOI: 10.1111/J.1755-148X.2010.00750.X |
0.307 |
|
| 2010 |
Shackleton M, Quintana E. Progress in understanding melanoma propagation Molecular Oncology. 4: 451-457. PMID 20655286 DOI: 10.1016/J.Molonc.2010.06.006 |
0.769 |
|
| 2010 |
Shackleton M. Normal stem cells and cancer stem cells: similar and different. Seminars in Cancer Biology. 20: 85-92. PMID 20435143 DOI: 10.1016/J.Semcancer.2010.04.002 |
0.41 |
|
| 2010 |
Quintana E, Shackleton M, Morrison SJ. Abstract PL03-02: Some cancers follow a stem cell model, while other cancers have common tumorigenic cells with little hierarchical organization Tumor Biology. DOI: 10.1158/1538-7445.Am10-Pl03-02 |
0.76 |
|
| 2009 |
Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 138: 822-9. PMID 19737509 DOI: 10.1016/J.Cell.2009.08.017 |
0.752 |
|
| 2009 |
Shackleton M, O'Reilly LA, Sutherland KD, Bath ML, Ellis S, Strasser A, Visvader JE, Lindeman GJ. Impaired lactation in mice expressing dominant-negative FADD in mammary epithelium. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 238: 1010-6. PMID 19301394 DOI: 10.1002/Dvdy.21917 |
0.401 |
|
| 2009 |
Johnson TM, Shackleton MJ, Quintana E, Fullen DR, Sabel MS. Melanoma: Do we need a hatchet or a scalpel? Archives of Dermatology. 145: 307-308. PMID 19289763 DOI: 10.1001/Archdermatol.2009.3 |
0.696 |
|
| 2008 |
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 456: 593-8. PMID 19052619 DOI: 10.1038/Nature07567 |
0.795 |
|
| 2008 |
Asselin-Labat ML, Vaillant F, Shackleton M, Bouras T, Lindeman GJ, Visvader JE. Delineating the epithelial hierarchy in the mouse mammary gland. Cold Spring Harbor Symposia On Quantitative Biology. 73: 469-78. PMID 19022771 DOI: 10.1101/Sqb.2008.73.020 |
0.398 |
|
| 2008 |
Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Research. 68: 7711-7. PMID 18829523 DOI: 10.1158/0008-5472.Can-08-1949 |
0.437 |
|
| 2007 |
Vaillant F, Asselin-Labat ML, Shackleton M, Lindeman GJ, Visvader JE. The emerging picture of the mouse mammary stem cell. Stem Cell Reviews. 3: 114-23. PMID 17873344 DOI: 10.1007/S12015-007-0018-2 |
0.358 |
|
| 2007 |
Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biology. 9: 201-9. PMID 17187062 DOI: 10.1038/Ncb1530 |
0.344 |
|
| 2006 |
Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ. Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute. 98: 1011-4. PMID 16849684 DOI: 10.1093/Jnci/Djj267 |
0.381 |
|
| 2006 |
Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature. 439: 84-8. PMID 16397499 DOI: 10.1038/Nature04372 |
0.355 |
|
| 2006 |
Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. Nature. 439: 993-7. PMID 16395311 DOI: 10.1038/Nature04496 |
0.366 |
|
| 2005 |
Sum EY, Shackleton M, Hahm K, Thomas RM, O'Reilly LA, Wagner KU, Lindeman GJ, Visvader JE. Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development. Oncogene. 24: 4820-8. PMID 15856027 DOI: 10.1038/Sj.Onc.1208638 |
0.355 |
|
| 2005 |
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, et al. Erratum: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans (Proceedings of the National Academy of Sciences of the United States of America (July 20, 2004) 101, 29 (10697-10702)) Proceedings of the National Academy of Sciences of the United States of America. 102. DOI: 10.1073/Pnas.0504548102 |
0.314 |
|
| 2004 |
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America. 101: 10697-702. PMID 15252201 DOI: 10.1073/Pnas.0403572101 |
0.323 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2003 |
Jefford M, Schnurr M, Toy T, Masterman KA, Shin A, Beecroft T, Tai TY, Shortman K, Shackleton M, Davis ID, Parente P, Luft T, Chen W, Cebon J, Maraskovsky E. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood. 102: 1753-63. PMID 12738673 DOI: 10.1182/Blood-2002-12-3854 |
0.296 |
|
| 2016 |
Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G, Sandhu S. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26861600 DOI: 10.1093/Annonc/Mdw056 |
0.296 |
|
| 2020 |
Ratnayake G, Reinwald S, Shackleton M, Moore M, Voskoboynik M, Ruben J, van Zelm MC, Yu D, Ward R, Smith R, Haydon A, Senthi S. Stereotactic radiotherapy combined with immunotherapy against metastatic melanoma: Long term results of a phase I clinical trial. International Journal of Radiation Oncology, Biology, Physics. PMID 32450331 DOI: 10.1016/J.Ijrobp.2020.05.022 |
0.287 |
|
| 2020 |
Nguyen J, Clements W, McLean C, Haydon A, Moore M, Yap KS, Mar V, Shackleton M. Metastatic melanoma presenting as intravenous tumour thrombus. Journal of Medical Imaging and Radiation Oncology. PMID 32227569 DOI: 10.1111/1754-9485.13019 |
0.278 |
|
| 2019 |
Guo C, Lewin J, Shackleton M. Personalised surveillance after treatment for high-risk cancer. Oncotarget. 10: 694-695. PMID 30774771 DOI: 10.18632/Oncotarget.26619 |
0.268 |
|
| 2015 |
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, ... ... Shackleton M, et al. Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature. PMID 26503049 DOI: 10.1038/Nature15716 |
0.258 |
|
| 2018 |
Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, ... ... Shackleton M, et al. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer (Oxford, England : 1990). 105: 88-102. PMID 30439628 DOI: 10.1016/J.Ejca.2018.09.027 |
0.252 |
|
| 2018 |
Tan L, Sandhu SK, Lee R, Li J, Callahan J, Raleigh J, Hatzimihalis A, Middlehurst P, Henderson M, Shackleton M, Haydon A, Gyorki D, Oudit D, Hicks RJ, Lorigan P, et al. Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii14-viii15. PMID 32136221 DOI: 10.1093/Annonc/Mdy269.050 |
0.25 |
|
| 2019 |
Ratnayake G, Reinwald S, Shackleton MJ, Moore MA, Voskoboynik M, Ruben J, Van Zelm M, Yu D, Ward R, Smith R, Haydon AM, Senthi S. Stereotactic radiotherapy combined with immunotherapy is safe and effective: Results from a phase I clinical trial. Journal of Clinical Oncology. 37: 9557-9557. DOI: 10.1016/J.Ijrobp.2019.06.502 |
0.248 |
|
| 2018 |
Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, Herschtal A, Spillane J, Gyorki D, Speakman D, Estall V, Donahoe S, Pohl M, Pope K, Chua M, ... ... Shackleton M, et al. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29659679 DOI: 10.1093/Annonc/Mdy124 |
0.236 |
|
| 2022 |
Huo CW, Gunadasa I, Gkolia P, Shackleton M, Hunn M. Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases. Melanoma Research. 33: 58-65. PMID 36545922 DOI: 10.1097/CMR.0000000000000864 |
0.213 |
|
| 2023 |
Edwards JM, Andrews MC, Burridge H, Smith R, Owens C, Edinger M, Pilkington K, Desfrancois J, Shackleton M, Senthi S, van Zelm MC. Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma. Clinical & Translational Immunology. 12: e1466. PMID 37692904 DOI: 10.1002/cti2.1466 |
0.204 |
|
| 2002 |
Brown SJ, Shackleton M, Salem H, Schmidt G. Gastro-colic fistula complicating primary (Al) amyloidosis. Journal of Gastroenterology and Hepatology. 17: 110-1. PMID 11895565 DOI: 10.1046/J.1440-1746.2002.02655.X |
0.191 |
|
| 2004 |
Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D, Chen W, Maraskovsky E, Cebon J. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immunity. 4: 9. PMID 15384929 |
0.189 |
|
| 2023 |
Hiong A, O'Day R, Fog LS, McKay D, McKenzie J, Ameratunga M, Joshua AM, Shackleton M. Globe salvage and vision preservation by neoadjuvant darovasertib and crizotinib in uveal melanoma. Ophthalmology. Retina. PMID 37852320 DOI: 10.1016/j.oret.2023.10.009 |
0.188 |
|
| 2021 |
Wang W, Smith JL, Carlino MS, Burmeister B, Pinkham MB, Fogarty GB, Christie DRH, Estall V, Shackleton M, Clements A, Wolfe R, Thao LTP, Paton EJ, Steel V, Williams NC. Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. Clinical and Translational Radiation Oncology. 30: 95-99. PMID 34458597 DOI: 10.1016/j.ctro.2021.08.006 |
0.184 |
|
| 2019 |
Banks PD, Lasocki A, Lau PKH, Sandhu S, McArthur G, Shackleton M. Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. Health Science Reports. 2: e115. PMID 30937392 DOI: 10.1002/hsr2.115 |
0.184 |
|
| 2016 |
Sandhu SK, Wong SQ, Vergara IA, Raleigh J, Callahan J, Ftouni S, Hatzimihalis A, Devbarna S, Doig K, Colebatch A, MirArnau G, Cullinane C, Gyorki DE, Kee D, Brady BM, ... Shackleton MJ, et al. Circulating tumor DNA (ctDNA) to track responses and to capture the genomic heterogeneity of metastatic melanoma. Journal of Clinical Oncology. 34: 9582-9582. DOI: 10.1200/JCO.2016.34.15_SUPPL.9582 |
0.184 |
|
| 2022 |
Yan MK, Adler NR, Pan Y, Chamberlain A, Kelly J, Yap K, Voskoboynik M, Haydon A, Shackleton M, Mar VJ. Yield of baseline imaging for distant metastases in high-risk primary melanoma. Journal of Surgical Oncology. PMID 35262187 DOI: 10.1002/jso.26846 |
0.181 |
|
| 2018 |
Britt K, Dall G, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell S, Ashworth A, Anderson R, Risbridger G, Shackleton M. Abstract P5-14-03: Withdrawn Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-14-03 |
0.178 |
|
| 2020 |
Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, ... ... Shackleton M, et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer. PMID 33087895 DOI: 10.1038/s41416-020-01121-y |
0.167 |
|
| 2024 |
Knox A, Wang T, Shackleton M, Ameratunga M. Symptomatic brain metastases in melanoma. Experimental Dermatology. 33: e15075. PMID 38610093 DOI: 10.1111/exd.15075 |
0.161 |
|
| 2021 |
Robertson SJ, Orme L, Teixeira R, Shamassi M, Newell F, Patch AM, Yeh I, Gard G, Wilmott J, Jackett L, LeBoit P, Fellowes A, MacArthur G, Fox S, Hayward NK, ... ... Shackleton M, et al. Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. Jama Dermatology. PMID 34076666 DOI: 10.1001/jamadermatol.2021.0025 |
0.154 |
|
| 2022 |
Dow E, Freimund A, Smith K, Hicks RJ, Jurcevic P, Shackleton M, James PA, Fellowes A, Delatycki MB, Fawcett S, Flowers N, Pertile MD, McGillivray G, Mileshkin L. Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model. Jco Precision Oncology. 5: 1001-1012. PMID 34994626 DOI: 10.1200/PO.20.00429 |
0.153 |
|
| 2022 |
Wong SQ, Raleigh JM, Callahan J, Vergara IA, Ftouni S, Hatzimihalis A, Colebatch AJ, Li J, Semple T, Doig K, Mintoff C, Sinha D, Yeh P, Silva MJ, Alsop K, ... ... Shackleton M, et al. Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. Jco Precision Oncology. 1: 1-14. PMID 35172485 DOI: 10.1200/PO.16.00009 |
0.149 |
|
| 2021 |
Berry W, Tan K, Haydon A, Shackleton M, Mar VJ. Reduced melanoma referrals during COVID-19 lockdown. Australian Journal of General Practice. PMID 33543153 DOI: 10.31128/AJGP-COVID-45 |
0.147 |
|
| 2005 |
Chen Q, Jackson H, Shackleton M, Parente P, Hopkins W, Sturrock S, MacGregor D, Maraskovsky E, Tai TY, Dimopoulos N, Masterman KA, Luke T, Davis ID, Chen W, Cebon J. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immunity. 5: 5. PMID 15755075 |
0.146 |
|
| 2022 |
Wang C, Zoungas S, Yan M, Wolfe R, Haydon A, Shackleton M, Voskoboynik M, Moore M, Andrews MC, Nicholls SJ, Mar V. Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study. Cardio-Oncology (London, England). 8: 23. PMID 36461057 DOI: 10.1186/s40959-022-00149-8 |
0.14 |
|
| 2021 |
Blood Z, Tran A, Caleo L, Saw R, Dieng M, Shackleton M, Soyer HP, Arnold C, Mann GJ, Morton RL. Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review. Bmj Open. 11: e040751. PMID 33574144 DOI: 10.1136/bmjopen-2020-040751 |
0.136 |
|
| 2022 |
Jobson D, Roffey B, Best R, Button-Sloan A, Cossio D, Evans S, Shang C, Moore J, Arnold C, Mann G, Shackleton M, Soyer HP, Morton RL, Zalcberg J, Mar V. Developing an Australian Melanoma Clinical Outcomes Registry (MelCOR): a protocol paper. Bmj Open. 12: e062139. PMID 36691164 DOI: 10.1136/bmjopen-2022-062139 |
0.135 |
|
| 2024 |
Walpole IR, Zaman FY, Zhao P, Marshall VM, Lin FP, Thomas DM, Shackleton M, Antolin AA, Ameratunga M. Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases. Clinical and Translational Medicine. 14: e1657. PMID 38629623 DOI: 10.1002/ctm2.1657 |
0.133 |
|
| 2003 |
Cebon J, Jäger E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, Gibbs S, Chen Q, Karbach J, Jackson H, MacGregor DP, Sturrock S, Vaughan H, Maraskovsky E, Neumann A, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immunity. 3: 7. PMID 12862418 |
0.132 |
|
| 2000 |
Shackleton M. Bt Technology Journal. 18: 73-75. DOI: 10.1023/A:1026525905077 |
0.12 |
|
| 2023 |
Shackleton M, Yeoh HL, Freilich K, Voskoboynik M, Moore M, Andrews MC, Haydon AM. Immune-related adverse events secondary to immunotherapy in oncology: A guide for general practice. Australian Journal of General Practice. 52: 378-385. PMID 37291817 DOI: 10.31128/AJGP-04-22-6408 |
0.114 |
|
| 2022 |
Yan MK, Adler NR, Wolfe R, Pan Y, Chamberlain A, Kelly J, Yap K, Voskoboynik M, Haydon A, Shackleton M, Mar VJ. The role of surveillance imaging for resected high-risk melanoma. Asia-Pacific Journal of Clinical Oncology. PMID 36540019 DOI: 10.1111/ajco.13913 |
0.111 |
|
| 2020 |
Byron Y, Nott L, Shackleton M. Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass. Melanoma Research. PMID 32976221 DOI: 10.1097/CMR.0000000000000696 |
0.109 |
|
| 2017 |
Sayers L, Lewin JH, Kee D, Walpole I, Sanelli A, Herschtal A, Spillane J, Gyorki DE, Speakman D, Estall V, Donahoe S, Pohl M, Pope K, Chua M, Sandhu SK, ... ... Shackleton MJ, et al. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Journal of Clinical Oncology. 35: 9563-9563. DOI: 10.1200/JCO.2017.35.15_SUPPL.9563 |
0.103 |
|
| 2015 |
Lewin JH, Sanelli A, Walpole I, Kee D, Henderson MA, Speakman D, Spillane J, Gyorki DE, Estall V, Te Marvelde L, Pope K, Chua M, McArthur GA, Hicks RJ, Shackleton MJ. Surveillance imaging with FDG-PET in the follow-up of melanoma patients at high risk of relapse. Journal of Clinical Oncology. 33: 9003-9003. DOI: 10.1200/JCO.2015.33.15_SUPPL.9003 |
0.097 |
|
| 2014 |
Gyorki DE, Spillane J, Speakman D, Shackleton M, Henderson MA. Current management of advanced melanoma: A transformed landscape Anz Journal of Surgery. DOI: 10.1111/ans.12673 |
0.094 |
|
| 2019 |
Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SM, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, ... ... Shackleton MJ, et al. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell & Melanoma Research. PMID 30767428 DOI: 10.1111/pcmr.12775 |
0.083 |
|
| 2017 |
Pires Da Silva IED, Johnpulle RAN, Banks PD, Grass GD, Smith JL, Everett AS, Goldinger SM, Roberts-Thomson R, Millward M, Glitza IC, Haydu LE, Atkinson V, Wang T, Eroglu Z, Conry RM, ... Shackleton MJ, et al. Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). Journal of Clinical Oncology. 35: 9513-9513. DOI: 10.1200/JCO.2017.35.15_SUPPL.9513 |
0.081 |
|
| 2023 |
Woollett A, Duncan J, Voskoboynik M, Shackleton M, Dooley M, Blum R, McPhee N, Wright T, Wong ZW, Dixon J, Jane SM. A capability framework to inform the fundamental requirements for clinical trial unit development, growth and long term success in outer metropolitan and rural areas. Contemporary Clinical Trials Communications. 32: 101072. PMID 36712185 DOI: 10.1016/j.conctc.2023.101072 |
0.064 |
|
| 2019 |
Ratnayake G, Reinwald S, Shackleton M, Voskoboynik M, Ruben J, van Zelm M, Yu D, Ward R, Smith R, Haydon A, Senthi S. Stereotactic Radiotherapy Combined with Immunotherapy Is Safe And Effective: Results From A Phase I Clinical Trial International Journal of Radiation Oncology*Biology*Physics. 105: S61. DOI: 10.1016/j.ijrobp.2019.06.502 |
0.063 |
|
| 2013 |
Bekele E, Toze S, Patterson B, Fegg W, Shackleton M, Higginson S. Evaluating two infiltration gallery designs for managed aquifer recharge using secondary treated wastewater. Journal of Environmental Management. 117: 115-20. PMID 23380303 DOI: 10.1016/j.jenvman.2012.12.018 |
0.06 |
|
| 2005 |
Matthiessen JN, Shackleton MA. Biofumigation: environmental impacts on the biological activity of diverse pure and plant-derived isothiocyanates. Pest Management Science. 61: 1043-51. PMID 15986402 DOI: 10.1002/ps.1086 |
0.054 |
|
| 2006 |
Saffre F, Halloy J, Shackleton M, Deneubourg JL. Self-organized service orchestration through collective differentiation. Ieee Transactions On Systems, Man, and Cybernetics. Part B, Cybernetics : a Publication of the Ieee Systems, Man, and Cybernetics Society. 36: 1237-46. PMID 17186800 DOI: 10.1109/TSMCB.2006.873214 |
0.051 |
|
| 2010 |
Toze S, Bekele E, Page D, Sidhu J, Shackleton M. Use of static Quantitative Microbial Risk Assessment to determine pathogen risks in an unconfined carbonate aquifer used for Managed Aquifer Recharge. Water Research. 44: 1038-49. PMID 19762063 DOI: 10.1016/j.watres.2009.08.028 |
0.044 |
|
| 2011 |
Shackleton M. Peter Swirski's Ars Americana Ars Politica: Partisan Expression in Contemporary American Literature and Culture American Studies in Scandinavia. 43: 128-130. DOI: 10.22439/ASCA.V43I1.4394 |
0.023 |
|
| 2015 |
Shackleton M. Maria Holmgren Troy, Elizabeth Kella, and Helena Wahlström's Making Home: Orphanhood, Kinship, and Cultural Memory in Contemporary American Novels American Studies in Scandinavia. 47: 122-124. DOI: 10.22439/ASCA.V47I1.5168 |
0.02 |
|
| 1989 |
Tashiro C, Clement R, Reid N, Orr D, Shackleton M. Determination of dioxins and furans in precipitation collected in urban and rural Ontario locations Chemosphere. 19: 535-540. DOI: 10.1016/0045-6535(89)90366-4 |
0.016 |
|
| 1992 |
Shackleton M. Robert M. Crunden's 'A Brief History of American Culture' American Studies in Scandinavia. 24: 58-59. DOI: 10.22439/ASCA.V24I1.2710 |
0.01 |
|
| 2021 |
Gaughran G, Zalcberg J, Hawkins CA, Shackleton M, Voskoboynik M. Improving regional access: Phase 1 teletrials in the era of COVID-19. Asia-Pacific Journal of Clinical Oncology. 17: 416-417. PMID 34291568 DOI: 10.1111/ajco.13558 |
0.01 |
|
| 2005 |
Saffre F, Hoile C, Shackleton M. Bandwidth management for the people Bt Technology Journal. 23: 232-239. DOI: 10.1007/S10550-005-0019-0 |
0.01 |
|
| 2004 |
Shackleton M, Saffre F, Tateson R, Bonsma E, Roadknight C. Autonomic Computing for Pervasive ICT — A Whole-System Perspective Bt Technology Journal. 22: 191-199. DOI: 10.1023/B:BTTJ.0000047132.31406.7F |
0.01 |
|
| 1990 |
Reid N, Orr D, Shackleton M, Lusis M, Tashiro C, Clement R. Monitoring dioxins and dibenzofurans in precipitation in Ontario Chemosphere. 20: 1467-1472. DOI: 10.1016/0045-6535(90)90299-9 |
0.01 |
|
| Hide low-probability matches. |